C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Cemsidomide Phase 1/2 Trial in Multiple Myeloma and non-Hodgkin’s Lymphoma Continues to Progress: Data from Both Indications to be Presented at the 66^th American Society of Hematology (ASH) Annual Meeting in San Diego, CA